Syndax to Highlight Late-Stage Programs and Unveil New Pipeline Assets at R&D Event

ConferenceSNDX-4321Positive

AI Analysis

Summary

Syndax announced plans to highlight late-stage programs and unveil new pipeline assets at an R&D event, including SNDX-4321, a novel mutant-selective allosteric EGFR inhibitor for NSCLC.

Importance:3/10

Sentiment:

0.30

pipeline expansionEGFR inhibitorNSCLCR&D eventlate-stage programs

Related Companies

$INTI

Read the original article

Published by GlobeNewswire Pharma on July 14, 2026 12:00 PM

Read Original